REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology. This Headquarters Project for REGENXBIO consolidates and expand labs and offices into a single building that allows for continuous operations. EwingCole designed the new 132,000 SF project to uniquely accommodate cGMP production with cell & gene manufacturing on the top floor. The facility also integrates research & development labs, offices, amenities, and support for the increased collaboration of all business lines. Based on future growth projections, the design team worked with the owner to plan flexibility for future expansion with a multi-floor strategy.